by Jay Bitkower | Dec 31, 2022 | Kidney Cancer News
On December 30, President Biden signed the FY2023 Omnibus Bill, which includes $50 million for the Kidney Cancer Research Program for this fiscal year ending on September 30, 2023. That brings the total funding for kidney cancer research, since 2006 when ACKC started...
by Jay Bitkower | Dec 27, 2022 | Therapeutics Updates
Dr. Toni Choueiri, the principal investigator, from Dana Farber Institute, presented the results of the much-anticipated Phase III trial, COSMIC-313, at the 2022 European Society for Medical Oncology (ESMO) Conference in Paris. COSMIC-313 is the first triplet drug...
by Jay Bitkower | Dec 20, 2022 | Therapeutics Updates
The following is a summary extracted from a set of guidelines issued during 2022 by the American Society for Clinical Oncology (ASCO) on how to medically treat metastatic kidney cancer for patients who have clear cell carcinoma (ccRCC). The guidelines were developed...
by Jay Bitkower | Jun 21, 2022 | ACKC News
It is said that in order to succeed one must be persistent and be prepared to take advantage of opportunities when they arise. ACKC’s decades-long effort to obtain Federal funding for kidney cancer research confirms the wisdom of that approach. Here’s the story. In...
by Jay Bitkower | Jun 20, 2022 | Therapeutics Updates
Oncologists generally prescribe adjuvant therapy to patients who not only have been diagnosed and treated for their disease but, also have a high probability that the disease will return. For example, in women with hormone-receptor-positive (HR+), the most common...
